CUA Educational Content

Canadian Expert discussion on the treatment and management considerations for

MIBC treatment regimens

Featuring: Aly-Khan Lalani & Peter Black

By participating in this program, participants can expect to:

  • Summarize key updates in the new CUA guidelines for MIBC and how they impact clinical decision-making in Canada 
  • Reflect on the latest advancements in perioperative treatments for patients with MIBC (NIAGARA and CM-274) and their potential implications for treatment strategies. 
  • Discuss treatment and management considerations for MIBC treatment regimens in the Canadian context, considering guideline updates, patient selection, and access to therapies.
Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Urological Association. You may claim a maximum of .5 hour of credit.

This program has received financial support from AstraZeneca Canada.

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy